<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-17</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-17T07:15:41.150Z</news:publication_date>
      <news:title>Biotech Catalysts to Watch: Key Developments Ahead for TENX and SION</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/ARGX/argenx-positive-results-phase-3-alkivia-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-17T05:00:00.000Z</news:publication_date>
      <news:title>argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.biopharmawatch.com/news/MESO/mesoblast-completes-patient-treatment-phase-3-trial</loc>
    <news:news>
      <news:publication>
        <news:name>BiopharmaWatch</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-17T00:35:00.000Z</news:publication_date>
      <news:title>Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain</news:title>
    </news:news>
  </url>
</urlset>